Physician profile
Gary H Payman
NPI 1265431266
$10,416.81
in general payments reported to CMS, 2019-2025
40 companies · $1,861 in 2025
The $1,861 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $527 · 2021: $1,415 · 2022: $1,652 · 2023: $1,533 · 2024: $1,725 · 2025: $1,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,076 · Education: $42.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,075.80 |
| Education | $42.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,833.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,325.15 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,251.86 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $971.88 | 2019-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $498.39 | 2019-2025 | Injectafer |
| Celgene Corporation | $438.39 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $285.19 | 2022-2025 | Dupixent |
| Pfizer INC. | $256.26 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $174.41 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $172.35 | 2019-2025 | Ocaliva |
| Boston Scientific Corporation | $148.45 | 2019 | |
| Gilead Sciences, INC. | $147.55 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $140.11 | 2019-2024 | Linzess |
| Ardelyx, INC. | $139.03 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $136.30 | 2021-2024 | Sucraid, Sucraid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Echosens North America, INC. | $116.29 | 2025 | Fibroscan |
| Conmed Corporation | $104.81 | 2022 | |
| Medtronic, INC. | $89.91 | 2024-2025 | Gi Genius, Interstim |
| Celltrion USA INC. | $78.70 | 2024-2025 | Zymfentra, Vegzelma |
| Merck Sharp & Dohme LLC | $75.02 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $73.90 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $64.65 | 2019-2023 | Rebyota |
| Lilly USA, LLC | $63.25 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $62.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $61.79 | 2021-2023 | Suflave |
| Genzyme Corporation | $60.46 | 2025 | |
| Novo Nordisk INC | $56.22 | 2025 | Wegovy |
| Organon LLC | $51.90 | 2022-2023 | Hadlima |
| Amgen INC. | $49.12 | 2019-2022 | |
| Shire North American Group INC | $43.24 | 2019 | |
| Biocon Biologics INC | $37.93 | 2025 | Yesintek |
| Intra-Sana Laboratories | $36.58 | 2022 | |
| Aimmune Therapeutics, INC. | $34.45 | 2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $24.88 | 2024-2025 | Voquezna |
| Sandoz INC. | $18.52 | 2025 | |
| W. L. Gore & Associates, INC. | $14.94 | 2022 | |
| Allergan, INC. | $14.54 | 2019 | |
| Covidien LP | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Payman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.